Cargando…
Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous and fatal disease. However, IPF treatment has been limited by the low drug delivery efficiency to lungs and dysfunctional “injured” type II alveolar epithelial cell (AEC II). Here, we present surface-engineered nanoparticles (PER NPs) loa...
Autores principales: | Chang, Xin, Xing, Lei, Wang, Yi, Yang, Chen-Xi, He, Yu-Jing, Zhou, Tian-Jiao, Gao, Xiang-Dong, Li, Ling, Hao, Hai-Ping, Jiang, Hu-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253157/ https://www.ncbi.nlm.nih.gov/pubmed/32518825 http://dx.doi.org/10.1126/sciadv.aba3167 |
Ejemplares similares
-
Monocyte as a prognostic marker in patients with idiopathic pulmonary fibrosis
por: Zhu, Shiping
Publicado: (2021) -
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021) -
Do Circulating Monocytes Promote and Predict Idiopathic Pulmonary Fibrosis Progression?
por: Fernandez, Isis E., et al.
Publicado: (2021) -
Update on therapeutic management of idiopathic pulmonary fibrosis
por: Tzouvelekis, Argyris, et al.
Publicado: (2015) -
Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of Developmental Programs?
por: Selman, Moisés, et al.
Publicado: (2008)